Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity (vol 117, 105447, 2021)

被引：0
|
作者：
Li, Ling [1 ]
Wu, Yinrong [1 ]
Yang, Zichao [1 ]
Xu, Chenglong [1 ]
Zhao, Huiting [1 ]
Liu, Jin [1 ]
Chen, Jingxuan [1 ]
Chen, Jianjun [1 ]
机构：
[1] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Peoples R China
来源：
BIOORGANIC CHEMISTRY | 2024年 / 150卷
关键词：
D O I：
10.1016/j.bioorg.2024.107616
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity
    Li, Ling
    Wu, Yinrong
    Yang, Zichao
    Xu, Chenglong
    Zhao, Huiting
    Liu, Jin
    Chen, Jingxuan
    Chen, Jianjun
    BIOORGANIC CHEMISTRY, 2021, 117
  • [2] Establishment of KRAS G12C mutant brain metastasis models for preclinical evaluation of KRAS G12C targeted anticancer therapy
    Chen, Qikuan
    Wang, Guilan
    Yin, Yingfei
    CANCER RESEARCH, 2024, 84 (06)
  • [3] Discovery of potent CNS-penetrant covalent KRAS G12C inhibitors
    Bae, Jae Hyun
    Lew, Erin D.
    Feng, Jun
    Gonzalez-Lopez, Marcos
    Oh, Joanne
    Fagan, Patrick
    Salie, Matt
    Isley, Nick
    Lam, Richard
    Irimia, Adriana
    Nevarez, Robin
    Lin, Bingzhen
    Congdon, Taylor
    Zhang, Jingchuan
    Xuan, Dawei
    Chen, Ping
    Vernier, Jean-Michel
    Shoemaker, Robert
    CANCER RESEARCH, 2022, 82 (12)
  • [4] Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents
    Li, Ling
    Zhao, Huiting
    Peng, Xiaopeng
    Liu, Jin
    Mai, Ruiyao
    Chen, Jingxuan
    Lin, Lin
    Chen, Ting
    Yan, Jun
    Shi, Jiaolong
    Chen, Jianjun
    BIOORGANIC & MEDICINAL CHEMISTRY, 2022, 71
  • [5] Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C
    Zeng, Mei
    Lu, Jia
    Li, Lianbo
    Feru, Frederic
    Quan, Chunshan
    Gero, Thomas W.
    Ficarro, Scott B.
    Xiong, Yuan
    Ambrogio, Chiara
    Paranal, Raymond M.
    Catalano, Marco
    Shao, Jay
    Wong, Kwok-Kin
    Marto, Jarrod A.
    Fischer, Eric S.
    Janne, Pasi A.
    Scott, David A.
    Westover, Kenneth D.
    Gray, Nathanael S.
    CELL CHEMICAL BIOLOGY, 2017, 24 (08): : 1005 - +
  • [6] Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents (vol 71, 116962, 2022)
    Li, Ling
    Zhao, Huiting
    Peng, Xiaopeng
    Liu, Jin
    Mai, Ruiyao
    Chen, Jingxuan
    Lin, Lin
    Chen, Ting
    Yan, Jun
    Shi, Jiaolong
    Chen, Jianjun
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 111
  • [7] The Research Progress of Direct KRAS G12C Mutation Inhibitors (vol 27, 631095, 2021)
    Yang, Ai
    Li, Min
    Fang, Mingzhi
    PATHOLOGY & ONCOLOGY RESEARCH, 2022, 27
  • [8] Establishment of KRAS G12C mutant patient-derived xenograft (PDX) models for pre-clinical evaluation of KRAS G12C targeted anticancer therapy.
    Shi, Wenting
    Tang, Xuzhen
    Zhang, Jingying
    Kuang, Xinhong
    Zhang, Yan
    Wang, Jingjing
    Gu, Qingyang
    Ji, Qunsheng
    CANCER RESEARCH, 2021, 81 (13)
  • [9] Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models
    Nakayama, Ayako
    Nagashima, Takeyuki
    Nishizono, Yoshihiro
    Kuramoto, Kazuyuki
    Mori, Kenichi
    Homboh, Kazuya
    Yuri, Masatoshi
    Shimazaki, Masashi
    BRITISH JOURNAL OF CANCER, 2022, 126 (05) : 744 - 753
  • [10] Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models
    Ayako Nakayama
    Takeyuki Nagashima
    Yoshihiro Nishizono
    Kazuyuki Kuramoto
    Kenichi Mori
    Kazuya Homboh
    Masatoshi Yuri
    Masashi Shimazaki
    British Journal of Cancer, 2022, 126 : 744 - 753
12345